Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours

por Millward, M, Underhill, C, Lobb, S, McBurnie, J, Meech, S J, Gomez-Navarro, J, Marshall, M A, Huang, B, Mather, C B
Publicado 2013